Med Life Sa · BVB:M

Med Life Sa — 9M 2018 Earnings Presentation

13 slides from Med Life Sa's earnings presentation, 2018

  1. Slide 1: Conference Call Presentation for 9M2018 Results

    Conference Call Presentation for 9M2018 Results

  2. Slide 2: Legal Disclaimer

    LEGAL DISCLAIMER This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat

  3. Slide 3: Topics of Discussion

    TOPICS OF DISCUSSION PAGE I. MAIN EVENTS OF 2018 4 II. KEY CHANGES 9M2018 vs 9M2017 6 III. MEDLIFE 9M2018 FINANCIAL SNAPSHOT 8 IV. KEY OPERATIONAL METRICS FOR 9M2018 11 V. Q&A SESSION 12 Page 3

  4. Slide 4: Main Events of 2018

    MAIN EVENTS OF 2018 ACQUISITIONS • 100% of the shares in Polisano (approved by the Competition Council in April 2018) • 90% of the shares in Ghencea Medical Center (finalized in May 2018) • 80% of the shares in Solomed Group (finalized in May 2018) • 100% of the shares in the medical platform Sfatul

  5. Slide 5: Main Events of 2018 (Cont.)

    MAIN EVENTS OF 2018 (Cont.) CREDIT FACILITIES CONTRACTED BY THE GROUP • MedLife signed a new syndicated credit facility with Banca Comercială Română, Raiffeisen Bank, BRD Groupe Société Générale and Banca Transilvania for refinancing its existing facilities, extending the maturity of the loans, rear

  6. Slide 6: Key Changes 9M2018 vs 9M2017

    KEY CHANGES 9M2018 vs 9M2017 Sales increased by : + 32.0% Pro-forma 9M2018 vs. IFRS 9M2017 SALES + 26.2% IFRS 9M2018 vs. IFRS 9M2017 vs. market increase by approx. 10% + 12.8% like2like Stable margin: 12.4% Pro-forma 9M2018 vs. 12.7% IFRS 9M2017 (fig_1 below) Absolute value of EBITDA increased by 29

  7. Slide 7: Key Changes 9M2018 vs 9M2017 (Cont.)

    KEY CHANGES 9M2018 vs 9M2017 (Cont.) IFRS EBITDA is consistent with CF before WC and other monetary changes, as IFRS EBITDA was 70.3m RON, 9.1% while CF before WC and other monetary changes was 70m RON. EBITDA Split of Pro-forma EBITDA between Owners of the Group / NCI for 9M2018: - 90.9% to Group O

  8. Slide 8: MedLife Group 9M2018 Financial Snapshot

    MEDLIFE GROUP 9M2018 FINANCIAL SNAPSHOT Consolidated Statement of Financial Position Consolidated Statement of Profit and Loss Page 8

  9. Slide 9: MedLife Group 9M2018 Financial Snapshot

    MEDLIFE GROUP 9M2018 FINANCIAL SNAPSHOT Consolidated Statement of Cash Flow Page 9

  10. Slide 10: MedLife Group 9M2018 Financial Snapshot: OPEX Evolution

    MEDLIFE GROUP 9M2018 FINANCIAL SNAPSHOT OPEX EVOLUTION Note: The Group recorded a 1.3 p.p. increase of operating expenses as % of sales in 9M2018 as compared to 9M2017. A. 0.4 p.p. decrease of “Consumable materials and repair materials” as % of Sales, generated by increased cost synergies and volume

  11. Slide 11: Key Operational Metrics for 9M2018

    KEY OPERATIONAL METRICS FOR 9M2018 Page 11

  12. Slide 12: Q&A Session

    © Med Life IV. Q&A SESSION eo Ras Page 12

  13. Slide 13: Thank You!

    THANK YOU! © MedLife

MedLife — 9M 2018 Earnings Presentation on 6ix